Purpose of review
Dyslipidemia is highly prevalent among patients living with chronic HIV infection and may confer increased risk of cardiovascular disease in this patient population. This review summarizes recent data investigating lipid abnormalities and its management in HIV-infected patients.
Studies in the last year have evaluated the effects of various lipid-lowering therapies not previously investigated in the HIV patient population. Rosuvastatin is a potent statin that appears to be well tolerated and effective in HIV-infected patients with hypercholesterolemia.
Dyslipidemia is common in HIV-infected individuals. Medical therapy of lipid disorders needs to take potential drug–drug interactions of lipid-lowering medications and antiretroviral agents into consideration.
Keywords: cardiovascular risk factors, HIV, lipids